Filtered By:
Condition: Thrombosis
Drug: Activase
This page shows you your search results in order of date. This is page number 12.
Order by Relevance | Date
Total 351 results found since Jan 2013.
Intravenous thrombolysis in CADASIL: report of two cases and a systematic review
ConclusionsAvailable data on intravenous thrombolysis in CADASIL patients are scarce but suggest that this treatment can be taken into consideration for these patients.
Source: Neurological Sciences - October 18, 2022 Category: Neurology Source Type: research
Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. eCollection 2022 Aug.ABSTRACTIntravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mounting evidence to support the routine use of Tenecteplase (TNK) to treat acute ischemic stroke. TNK is a genetically modified tPA with higher fibrin specificity, longer half-life, and reduced systemic coagulopathy. In this il...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Annie Zhu Phavalan Rajendram Eric Tseng Shelagh B Coutts Amy Y X Yu Source Type: research
Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups a...
Source: BMC Neurology - September 20, 2022 Category: Neurology Authors: Huanhuan Lu, Siyi Li, Xin Zhong, Shuxuan Huang, Xue Jiao, Guoyong He, Bingjian Jiang, Yuping Liu, Zhili Gao, Jinhong Wei, Yushen Lin, Zhi Chen and Yanhua Li Tags: Research Source Type: research
Efficacy and safety of alteplase on treatment of acute single small subcortical infarction
CONCLUSION: Patients with SSSI in the anterior circulation are more likely to achieve 3 months favorable outcomes than those who were treated with standard medical care, however treatment with alteplase may not prevent occurrence of END.PMID:36043775 | DOI:10.2174/1567202619666220829111211
Source: Current Neurovascular Research - August 31, 2022 Category: Neurology Authors: Kilanga Marcelinus Hongbing Liu Ke Zhang Ce Zong Hongxun Yang Yuan Gao Bo Song Yuming Xu Source Type: research
Treatments in Ischemic Stroke: Current and Future
Background and Aim: Despite progress made over the last 30 years, stroke is still a leading cause of disability and mortality; likewise, its burden is expected to increase over the next decades, due to population growth and aging. The development of drugs with better safety-efficacy profiles as well as strategies able to improve ischemic stroke management from the pre-hospital setting is needed.Summary: The pathophysiology of ischemic stroke involves multiple pathways resulting in cerebral artery obstruction and brain tissue ischemia. To date, the only approved drug for acute ischemic stroke is intravenous thrombolytic alt...
Source: European Neurology - August 2, 2022 Category: Neurology Source Type: research
Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?
AbstractPurpose of reviewAlteplase has been the thrombolytic of choice for acute ischaemic stroke for more than two decades. A thrombolytic which is easier to administer and with improved or comparable safety and efficacy is desirable. Tenecteplase has emerged as a potential successor, and its off-license use in acute ischaemic stroke has increased in recent years. We aimed to examine the evidence base for each drug and discuss their use in varying patient populations in acute ischaemic stroke.Recent findingsSeveral trials comparing tenecteplase and alteplase have reported very recently with the results of the ACT trial st...
Source: Current Treatment Options in Neurology - July 30, 2022 Category: Neurology Source Type: research
E-048 Antithrombotics for emergent stenting in acute stroke
ConclusionTirofiban continuous infusion is a safe and possibly effective strategy for emergent stenting in acute ischemic stroke.Disclosures S. Lahoti: None. K. Limaye: None. C. Zevallos: None. K. Dlouhy: None. M. Hayakawa: None. E. Samaniego: None. D. Hasan: None. S. Ortega: 2; C; Medtronic, Stryker Neurovascular, Microvention. C. Derdeyn: 1; C; Siemens Healthineers. 4; C; Euphrates Vascular, Inc. 6; C; DSMB: Penumbra (MIND), NoNO (ESCAPE NA1 and FRONTIER).
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Lahoti, S., Limaye, K., Zevallos, C., Dlouhy, K., Hayakawa, M., Samaniego, E., Hasan, D., Ortega, S., Derdeyn, C. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research
EE477 Budgetary Impact Analysis of Alteplase - Recombinant Tissue Plasminogen Activator (RTPA) - As a Thrombolytic Treatment for Acute Ischemic Stroke in Colombia
to evaluate the potential impact on costs and health outcomes of increasing the proportion of patients with acute ischemic stroke (AIS) who are thrombolyzed with alteplase in Colombia and of reducing the time to initiate treatment.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: P Lasalvia Source Type: research
Budgetary impact analysis of alteplase - recombinant tissue plasminogen activator (rtPA) - as a thrombolytic treatment for acute ischemic stroke in Colombia
CONCLUSIONS: Doubling the number of patients with AIS who are thrombolyzed would lead to reductions in the number of patients with sequelae and would require a budgetary effort of 5.5-7.0%. The early initiation of treatment (0-180minutes) gives an additional benefit in reducing the number of sequelae and a lower budgetary impact than initiation within the last time window (181-270minutes).PMID:35702977 | DOI:10.1080/14737167.2022.2089655
Source: Expert Review of Pharmacoeconomics and Outcomes Research - June 15, 2022 Category: Health Management Authors: Yaneth Gil-Rojas Pieralessandro Lasalvia Source Type: research
